ALK and non-small cell lung carcinoma: For example, EGFR and ALK/ROS1 inhibitors show promising results in patients with NSCLC-BM.20-24 Given this, the poor prognosis of NSCLC-BM, and the numerous approved therapies for metastatic NSCLC, the presence of the associated biomarkers for these approved agents within NSCLC-BM warrants further study.